1-Hydroxypyrene
(Synonyms: 1-羟基芘) 目录号 : GC60448
1-羟基芘 (1-Hydroxypyrene，1 - OHP) 是一种人体代谢产物，也是一种广泛使用的生物标志物，可作为暴露于多环芳烃 (PAH) 的指标
Cas No.:5315-79-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
1-Hydroxypyrene, a biomarker of exposure to polycyclic aromatic hydrocarbons (PAHs), is analyzed in urine samples. 1-Hydroxypyrene is the major biomarker of exposure to pyrenes[1].
[1]. Fernando Freitas, et al. Urinary 1-hydroxypyrene Is Associated With Oxidative Stress and Inflammatory Biomarkers in Acute Myocardial Infarction. Int J Environ Res Public Health
| Cas No. | 5315-79-7 | SDF | |
| 别名 | 1-羟基芘 | ||
| Canonical SMILES | OC1=C(C2=C34)C=CC4=CC=CC3=CC=C2C=C1 | ||
| 分子式 | C16H10O | 分子量 | 218.26 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.5817 mL | 22.9085 mL | 45.8169 mL |
| 5 mM | 0.9163 mL | 4.5817 mL | 9.1634 mL |
| 10 mM | 0.4582 mL | 2.2908 mL | 4.5817 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
1-Hydroxypyrene mediates renal fibrosis through aryl hydrocarbon receptor signalling pathway
Br J Pharmacol 2022 Jan;179(1):103-124.PMID:34625952DOI:10.1111/bph.15705.
Background and purpose: In chronic kidney disease (CKD), patients inevitably reach end-stage renal disease and require renal transplant. Evidence suggests that CKD is associated with metabolite disorders. However, the molecular pathways targeted by metabolites remain enigmatic. Here, we describe roles of 1-Hydroxypyrene in mediating renal fibrosis. Experimental approach: We analysed 5406 urine and serum samples from patients with Stage 1-5 CKD using metabolomics, and 1-Hydroxypyrene was identified and validated using longitudinal and drug intervention cohorts as well as 5/6 nephrectomised and adenine-induced rats. Key results: We identified correlations between the urine and serum levels of 1-Hydroxypyrene and the estimated GFR in patients with CKD onset and progression. Moreover, increased 1-Hydroxypyrene levels in serum and kidney tissues correlated with decreased renal function in two rat models. Up-regulated mRNA expression of aryl hydrocarbon receptor and its target genes, including CYP1A1, CYP1A2 and CYP1B1, were observed in patients and rats with progressive CKD. Further we showed up-regulated mRNA expression of aryl hydrocarbon receptor and its three target genes, plus up-regulated nuclear aryl hydrocarbon receptor protein levels in mice and HK-2 cells treated with 1-Hydroxypyrene, which caused accumulation of extracellular matrix components. Treatment with aryl hydrocarbon receptor short hairpin RNA or flavonoids inhibited mRNA expression of aryl hydrocarbon receptor and its target genes in 1-hydroxypyrene-induced HK-2 cells and mice. Conclusion and implications: Metabolite 1-Hydroxypyrene was demonstrated to mediate renal fibrosis through activation of the aryl hydrocarbon receptor signalling pathway. Targeting aryl hydrocarbon receptor may be an alternative therapeutic strategy for CKD progression.
Urinary 1-Hydroxypyrene and other PAH metabolites as biomarkers of exposure to environmental PAH in air particulate matter
Toxicol Lett 1999 Sep 5;108(2-3):191-9.PMID:10511262DOI:10.1016/s0378-4274(99)00089-2.
Humans are exposed to polycyclic aromatic hydrocarbons (PAHs) from occupational, environmental, medicinal and dietary sources. PAH metabolites in human urine can be used as biomarkers of internal dose to assess recent exposure to PAHs. The most widely used urinary PAH metabolites are 1-Hydroxypyrene (1-OHP) or 1-hydroxypyrene-O-glucuronide (1-OHP-gluc), the major form of 1-OHP in human urine, because of their relatively high concentration and prevalence in urine and their relative ease of measurement. Elevated levels of 1-OHP or 1-OHP-gluc have been demonstrated in smokers, in patients receiving coal tar treatment (vs. pre-treatment), in postshift road pavers or coke oven workers, and in subjects ingesting charbroiled meat. This metabolite is found (at low levels) in most human urine samples, even in persons without apparent occupational or smoking exposure. Recent studies suggest that environmental exposure to PAHs (and air particles) is associated with increased excretion of 1-OHP-gluc or 1-OHP. These findings raise the possibility of using urinary concentration of 1-OHP-gluc, or another PAH metabolite, as a surrogate biomarker of exposure to airborne fine (sooty) particulate matter--the major source of PAHs in polluted air. Reported associations between ambient particulate matter concentrations and health effects among adults and children, including respiratory disease and mortality, indicate the need for biomarkers of fine particle exposure. If validated, such biomarkers would be useful in supplementing and refining exposure information obtained by ambient monitoring.
Urinary 1-Hydroxypyrene (1-HP) in environmental and occupational studies--a review
Int J Hyg Environ Health 2008 Oct;211(5-6):471-503.PMID:18222724DOI:10.1016/j.ijheh.2007.09.012.
A total of 132 studies were identified, of which 25 studies addressed environmental exposure to polycyclic aromatic hydrocarbons (PAHs) in the general population. Of these 9 studies included children. Of 101 studies among workers in various occupations, 32 studies were in petrochemical industries, 29 studies in foundries, 14 studies in asphalt work, 21 studies working in urban air, 6 studies in combustion, 3 studies in soil remediation, and 2 studies in printing. Environmental and occupational studies were identified through an extensive search of the PubMed database up to November 2006. The aim of this review was to provide an overview of studies using urinary 1-Hydroxypyrene (1-HP) as a biomarker of environmental and occupational exposure to PAHs. Hereby, we aim to support the current validation of 1-HP by summarizing the evidence of specific PAH exposure and1-HP associations in humans. Urine from more than 7000 children from 8 countries and 3400 adults from 9 countries were included in the 25 studies assessing environmental exposure to PAH. Among the occupational studies 7500 men and women gave urine samples to assess occupational PAH exposure. When measuring biomarkers in urine, volume (and time) or concentrations of creatinine are often used to standardize for diuresis. To be able to compare the included studies we recalculated the given concentrations to mumol 1-HP/mol creatinine. In conclusion, the highest concentrations of urinary 1-HP are found among workers in petrochemical industries among coke-oven workers. Occupational PAH exposure was the major factor determining high urinary concentration of 1-HP. The highest concentrations were observed among workers in the petrochemical industry at work places in Taiwan and China. To evaluate environmental and low-level occupational exposure to PAH it is crucial to provide knowledge on intra- and inter-individual variation in the evaluation of 1-HP. The highest contribution originates from environmental tobacco smoke, but also different country, cooking culture, and behavior influences urinary of 1-HP.
Urinary 1-Hydroxypyrene in occupationally-exposed and non-exposed individuals in Silesia, Poland
Ann Agric Environ Med 2018 Dec 20;25(4):625-629.PMID:30586979DOI:10.26444/aaem/75940.
Introduction: The aim of presented study was comparison of urinary 1-Hydroxypyrene concentration among coke plant workers (before and after working week) and among non-exposed individuals from the same area, taking smoking status into consideration. Material and methods: 647 coke plant workers and 206 individuals living in the same area were analysed with respect to urinary 1-OHP concentration and smoking status. Urinary samples were measured using high performance liquid chromatography (HPLC) with fluorescent detection. Concentrations were normalized with respect to creatinine concentration. For workers, two samples were collected before and after working week. Multiple regression was performed to distinguish and quantify the influence of cigarette smoking and occupational PAH exposition on the urinary 1-OHP levels. Results: Average urinary 1-OHP concentration of samples collected before the working week was: 1.07 μg/g; after the working week: 2.36 μg/g and for control: 0.74 μg/g. The samples collected at the beginning of the working week were not suitable for assessment of the workers' background (non-occupational) exposition. Smoking cigarettes induced a rise in urinary 1-OHP level by 16%, on average (CI: 5% - 28%), and working for a whole working week at the coke plant made urinary 1-OHP levels, on average, 3.21 times higher (CI: 2.91 - 3.54). Conclusions: Working at the coke plant increases significantly urinary 1-OHP concentration in comparison to non-occupationally exposed individuals, both for samples collected before and after the working week. Smoking remains a significant source of PAHs exposition, despite the fact that occupational exposure is greater. Health promotion programmes should address both the occupational health risks reduction and smoking prevention.
Oxidation of pyrene, 1-Hydroxypyrene, 1-nitropyrene and 1-acetylpyrene by human cytochrome P450 2A13
Xenobiotica 2016;46(3):211-24.PMID:26247835DOI:10.3109/00498254.2015.1069419.
1. The polycyclic hydrocarbons (PAHs), pyrene, 1-Hydroxypyrene, 1-nitropyrene and 1-acetylpyrene, were found to induce Type I binding spectra with human cytochrome P450 (P450) 2A13 and were converted to various mono- and di-oxygenated products by this enzyme. 2. Pyrene was first oxidized by P450 2A13 to 1-Hydroxypyrene which was further oxidized to di-oxygenated products, i.e. 1,8- and 1,6-dihydroxypyrene. Of five other human P450s examined, P450 1B1 catalyzed pyrene oxidation to 1-Hydroxypyrene at a similar rate to P450 2A13 but was less efficient in forming dihydroxypyrenes. P450 2A6, a related human P450 enzyme, which did not show any spectral changes with these four PAHs, showed lower activities in oxidation of these compounds than P450 2A13. 3. 1-Nitropyrene and 1-acetylpyrene were also found to be efficiently oxidized by P450 2A13 to several oxygenated products, based on mass spectrometry analysis. 4. Molecular docking analysis supported preferred orientations of pyrene and its derivatives in the active site of P450 2A13, with lower interaction energies (U values) than observed for P450 2A6 and that several amino acid residues (including Ala-301, Asn-297 and Ala-117) play important roles in directing the orientation of these PAHs in the P450 2A13 active site. In addition, Phe-231 and Gly-329 were found to interact with pyrene to orient this compound in the active site of P450 1B1. 5. These results suggest that P450 2A13 is one of the important enzymes that oxidizes these PAH compounds and may determine how these chemicals are detoxicated and bioactivated in humans.